BOCA RATON, FL, January 11, 2011 – There’s renewed hope for tens of millions worldwide with neurological vision loss who erroneously believe blindness due to stroke, brain cancer or brain injury to be untreatable. Medical device innovator Vycor Medical, Inc. (OTCBB: VYCO) has acquired NovaVision, Inc. (www.NovaVision.com), the only provider of progressive, scientifically based technologies that reverse and restore neurological visual loss. Together the companies will promote NovaVision’s FDA-approved, non-invasive light stimulation-based Vision Restoration Therapy (VRT) platform clinically proven to permanently restore lost vision resulting from stroke, brain cancer, traumatic or other acquired brain injury.
“With nearly 90% of VRT patients surveyed citing at least one significant benefit as a result of the therapy, a full 88% of patients noted a significant improvement in overall quality of life,” notes Tom Bridges NovaVision vice president of sales and marketing.”
“On average VRT patients permanently recover 5 degrees of central vision, a critical gain for conducting many daily activities,” Bridges notes. “While 5 degrees may sound like a small difference, clinical data shows it can have an exceptional impact on patients’ lives. Improvements range from increased safety, since studies show that most adult hip fractures are due to vision-related falls, to reading, watching TV, grooming, hobbies, sports, and, in some cases, the ability to drive again. As important, many patients report they’ve regained their self-esteem at a much higher level.”
“While other rehabilitation modalities such as speech, physical and occupational therapy have been considered a standard of care for stroke and traumatic brain injury, our innovative Vision Restoration Therapy addresses the unmet need for vision rehabilitation,” continues Bridges. “Unlike other therapies that help patients simply compensate for, or adjust to, their vision loss, VRT can actually permanently restore visual function and, thus, has a more significant impact on a patient’s emotional and physical well-being.”
More than 10 years of research and data support the efficacy of NovaVision’s neurostimulation therapy approach to be available by a prescription from any eye doctor, neurologist or physiatrist in the U.S.
How VRT Works
FDA-cleared in 2003, VRT has been proven to improve the vision and quality of life for stroke and brain injury survivors through a daily non-invasive therapeutic modality. NovaVision’s VRT device uses the eyes as conduits to deliver light-based stimuli to the brain to induce and accelerate neuroplasticity - the brain's ability to adapt and form new connections to overcome injury. The VRT diagnostic program maps areas where vision may be improved, while proprietary algorithms generate a customized neurostimulation therapy specific to each patient that activates the appropriate region within the brain's vision-processing areas. VRT remaps the brain’s visual system and expands the visual field of the patient to a more normal level, permanently restoring a measure of lost vision.
Vision rehabilitation therapy is performed on a leased device twice-daily for six months at home. During each session, patients focus on a central point displayed on the device's screen and respond every time they see light stimuli appear. The light stimuli are presented in the area most likely to recover visual function, an area which will change as therapy progresses and vision is improved. Therapy is regularly updated and monitored. Patients are advised to take breaks during therapy and to take one day of therapy off per week.
Consumers concerned they may be visually impaired may log on to take NovaVision’s free Online Neurological Vision Loss Test at http://www.helpforvisionloss.com/NVisionTest.html.
Post VRT 8.5 Degree Improvement
About NovaVision, Inc.
With headquarters in Boca Raton, Florida, Vycor Medical, Inc. (OTCBB:VYCO) subsidiary NovaVision, Inc. researches, develops and provides science-driven neurostimulation therapy and other medical technology solutions that restore sight to patients with neurological vision impairments. The company’s proprietary, award-winning Visual Restoration Therapy (VRT) platform is FDA-approved and clinically proven to restore lost vision resulting from stroke, brain cancer, traumatic brain injury (“TBI”), or other acquired brain injury. VRT can be prescribed by any eye doctor, neurologist or physiatrist. NovaVision also provides devices that aid in the diagnosis of visual field deficits: an Inpatient Device for assessment and therapeutic use in rehabilitation centers, and its Head Mounted Perimeter (HMPTM) - a portable and ADA-compliant instrument to aid in the assessment of visual field deficits. Among other honors and accolades, NovaVision has received the "Best of Boca Raton Award" in the Doctors Equipment & Supplies Category by the U.S. Local Business Association (USLBA); the "Heavy Hitter in Healthcare" award by the South Florida Business Journal ; and "Hero in Medicine Award" by the Palm Beach County Medical Society Services. For more information, log on to www.NovaVision.com or call 888.205.0800.
About Vycor Medical, Inc.
Vycor Medical, Inc. (VYCO.BB) is a medical device company committed to making brain, spinal and other surgical procedures safer and more effective and, through its NovaVision, Inc. subsidiary, providing Vision Restoration Therapy (VRT) to a broad range of patients. The company’s flagship, Patent Pending ViewSite™ Surgical Access Systems represent an exciting new breed of retraction technology that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor’s innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, and CE marketing and HPB licensing in Canada. For more information visit www.VycorMedical.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the abovementioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.